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Abstract
HIV sensory neuropathy and distal neuropathic pain (DNP) are common, disabling complications associated with
combination antiretroviral therapy (cART). We previously associated iron-regulatory genetic polymorphisms with a reduced
risk of HIV sensory neuropathy during more neurotoxic types of cART. We here evaluated the impact of polymorphisms in
19 iron-regulatory genes on DNP in 560 HIV-infected subjects from a prospective, observational study, who underwent
neurological examinations to ascertain peripheral neuropathy and structured interviews to ascertain DNP. Genotype-DNP
associations were explored by logistic regression and permutation-based analytical methods. Among 559 evaluable
subjects, 331 (59%) developed HIV-SN, and 168 (30%) reported DNP. Fifteen polymorphisms in 8 genes (p,0.05) and 5
variants in 4 genes (p,0.01) were nominally associated with DNP: polymorphisms in TF, TFRC, BMP6, ACO1, SLC11A2, and
FXN conferred reduced risk (adjusted odds ratios [ORs] ranging from 0.2 to 0.7, all p,0.05); other variants in TF, CP, ACO1,
BMP6, and B2M conferred increased risk (ORs ranging from 1.3 to 3.1, all p,0.05). Risks associated with some variants were
statistically significant either in black or white subgroups but were consistent in direction. ACO1 rs2026739 remained
significantly associated with DNP in whites (permutation p,0.0001) after correction for multiple tests. Several of the same
iron-regulatory-gene polymorphisms, including ACO1 rs2026739, were also associated with severity of DNP (all p,0.05).
Common polymorphisms in iron-management genes are associated with DNP and with DNP severity in HIV-infected
persons receiving cART. Consistent risk estimates across population subgroups and persistence of the ACO1 rs2026739
association after adjustment for multiple testing suggest that genetic variation in iron-regulation and transport modulates
susceptibility to DNP.
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Introduction
The success of combination antiretroviral therapy (cART) in
human immunodeficiency virus (HIV) infection has focused
attention on addressing long-term complications that reduce
quality of life, such as peripheral neuropathy [1]. Peripheral
neuropathy in HIV infection is a distal symmetric, often painful,
sensory polyneuropathy associated with the virus itself and/or to
toxic effects of certain antiretroviral drugs, particularly the
dideoxy-nucleoside reverse-transcriptase inhibitors (so-called ‘‘D-
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drug’’ NRTIs) such as didanosine and stavudine [2,3]. Clinically
and histopathologically, neuropathy due to HIV infection in the
pre-cART era and the neuropathy associated with cART toxicity
are usually indistinguishable; both are encompassed by the term
‘‘HIV sensory neuropathy’’ (HIV-SN). HIV-SN may first manifest
or worsen upon initiation of cART and is associated with sensory
loss, paresthesias, and distal neuropathic pain (DNP) or dysesthe-
sias. The known mitochondrial toxicity of D-drugs and dysregu-
lated inflammation have both been implicated in its pathogenesis,
but the pathophysiology of HIV-SN remains incompletely
understood [2,4–8].
Development of DNP is particularly disabling [9–11], because
the symptoms respond poorly to analgesic medications that are
used to treat other types of neuropathic pain [1,12–15]. HIV-SN
therefore has an adverse impact on quality of life, social and
emotional functioning, and neuropsychological test performance,
and DNP in particular contributes to depression, physical
deconditioning, and non-adherence to treatment [10,11,16–18].
Although substitution of less toxic antiretroviral drugs lowers the
risk of HIV-SN, older D-drugs like stavudine are likely to remain
in use in low-resource settings for some time as part of generic,
fixed-dose cART regimens, and the study of HIV-SN and DNP
remains very relevant [19,20]. Improved understanding of the
biological mechanisms underlying painful HIV-SN may lead to
better ways of categorizing and therapeutically targeting DNP
[21–23].
Iron is a critical micronutrient for metabolically active cells such
as neurons, and a carefully controlled supply of iron is essential for
mitochondrial function, axonal transport, and myelination [24–
26]. Iron transport also plays an important role in regulating
macrophage-mediated inflammation via the hepcidin pathway
[27–30]. Hepcidin, a peptide hormone which is synthesized in the
liver in response to inflammatory stimuli, leads to iron sequestra-
tion within the reticuloendothelial cell (macrophage-monocyte)
compartment, potentiating macrophage oxidative killing via
Fenton chemistry while reducing availability of iron to micro-
organisms. We previously reported associations between iron-
loading, single-nucleotide polymorphisms (SNPs) in the hemo-
chromatosis (HFE) gene and reduced risk of HIV-SN in HIV-
infected individuals exposed to D-drug-containing cART [31].
While improved cellular and mitochondrial iron delivery might
play a protective role in individuals with HFE variants, in whom
the action of hepcidin is reduced, these associations could also be
explained by the known linkage of HFE to the HLA Class I locus
and thereby to other immunomodulatory haplotypes [31,32].
Studies of non-HLA-linked genetic variants that are prevalent in
racially diverse populations, unlike HFE gene variants, are needed
to determine whether iron-transport is of fundamental importance
in susceptibility to HIV-SN and neuropathic symptoms like DNP.
We hypothesized that like HFE variants, common variants in
other iron-management but non-HLA-Class I-linked genes mod-
ulate susceptibility to cART-associated HIV-SN and DNP in
HIV-infected individuals, and that these genes impact neuropathy
phenotypes independent of race/ethnicity and disease-related
factors. This study assessed the role of variants in key iron-
transport and iron-regulatory genes (henceforth termed ‘‘the
ferrome’’ for brevity) in susceptibility to neuropathy phenotypes
in a racially diverse, HIV-infected population, the CNS HIV
Antiretroviral Therapy Effects Research (CHARTER) Cohort.
CHARTER is the largest U.S.-based prospective study of
neurological complications in HIV/AIDS in the cART era [33].
Particular strengths of CHARTER include its clear definition of
neurological phenotypes and sensitive and specific methods of
ascertaining HIV-SN. This analysis specifically targeted genes that
encode components of the nuclear and mitochondrial ferrome, for
which SNP genotypes were available from a genomic study
conducted previously in CHARTER. In addition to several SNPs
that were nominally associated with DNP, a common variant
(rs2026739) in the cytoplasmic aconitase gene (ACO1) was
identified to be statistically associated with DNP after multiple-
testing correction.
Patients and Methods
Study population
The CHARTER Study is a prospective, observational study
conducted at six outpatient centers within the U.S.: Johns Hopkins
University, Baltimore, Maryland; Mount Sinai School of Medi-
cine, New York, NY; the University of California, San Diego, CA;
the University of Texas Medical Branch, Galveston, TX; the
University of Washington, Seattle, WA; and Washington Univer-
sity, St Louis, MO. Data collection was standardized across
centers and employed a protocol of comprehensive neuromedical,
neurobehavioral, and laboratory assessments, including: nadir
CD4+ T-cell count, cART history, D-drug exposure, history of a
major depressive disorder, and demographic information (from
structured interviews), as well as current CD4+ T-cell count, HIV
plasma viral load, and hepatitis C viral serology (from laboratory
data). Further details regarding CHARTER Study eligibility and
enrollment procedures have been reported previously [1]. A subset
of CHARTER Study subjects (N = 579) was recruited between
2003 and 2007 to a cross-sectional genomic sub-study of
peripheral neuropathy. Genetic study eligibility criteria included
the ability to provide details of cART use and to undergo a
structured interview and examination for signs/symptoms of HIV-
SN; individuals with active opportunistic infections, uncontrolled
psychiatric disorders, or who were unable to cooperate with
detailed evaluations over the course of a full day were excluded.
Ethics Statement. The CHARTER Study and this study
were approved by the University of California-San Diego Human
Research Protections Program (Biomedical Institutional Review
Board) and by the Institutional Review Boards (IRBs) of the
following participating CHARTER institutions: the Johns Hop-
kins University School of Medicine IRB, Icahn School of Medicine
at Mount Sinai IRB, University of Texas (Medical Branch) IRB,
University of Washington School of Medicine IRB, and Wash-
ington University -St. Louis School of Medicine IRB. The present
study was conducted according to the principles expressed in the
Declaration of Helsinki. All study subjects whose data are reported
herein provided written informed consent.
Ascertainment of neuropathy and distal neuropathic
pain
Standardized, targeted neurological examinations were per-
formed by physicians and nurses trained in neurological AIDS
disorders. HIV-SN and DNP were identified using criteria
published previously [1,10]. Briefly, participants were queried at
baseline and each follow-up visit about symptoms of HIV-SN and
DNP, specifically, tingling, or burning, aching, shooting, or
stabbing pain in a bilateral, predominantly distal distribution
(e.g., in the fingers and toes only, extending to the ankles or wrists,
or extending to the knees or elbows). If subjects endorsed tingling
in this distribution, they were considered to have paresthesias; if
they endorsed any of the pain symptoms in this distribution, they
were considered to have a positive self-report of DNP; loss of
sensation in the lower extremities was also assessed on examina-
tion. HIV-SN cases were defined by the bilateral presence of at
least one of the following signs at any visit: diminished vibration
Iron-Regulatory Genes and HIV-Associated Neuropathic Pain
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sense, reduced sharp-dull discrimination in the feet and toes,
reduced ankle reflexes, and DNP cases by the above-mentioned
pain symptoms; controls did not have any of these signs or
symptoms of peripheral nerve disease. DNP was also classified into
the following 5 severity levels by structured survey; none, slight
(occasional, fleeting), mild (frequent), moderate (frequent, dis-
abling) or severe (constant, daily, disabling, and requiring
treatment with analgesics or other medications).
Genomic DNA isolation and gene selection
Genomic DNA was isolated from whole blood samples using
PUREGENE (Gentra Systems Inc., Minneapolis, MN, USA).
Samples were subjected to whole-genome nuclear genotyping
using the Affymetrix Genome-Wide Human SNP Array 6.0
platform (Affymetrix, Inc., Santa Clara, CA). Among 579
extracted samples, 560 yielded analyzable genotypes that passed
quality-control filters using the Platform for the Analysis,
Translation, and Organization of large scale data (PLATO)
[34]. Sample genotyping efficiency was 95%. Variants with less
than 95% genotyping efficiency or minor allele frequencies (MAFs)
less than 1% in the study population were excluded from analysis.
Genes reported in the published literature to be associated with
iron metabolism and/or neurological phenotypes were searched in
the publicly available Online Mendelian Inheritance in Man
database (http://www.ncbi.nlm.nih.gov/omim). We then identi-
fied 20 genes based on their well-recognized direct or indirect
involvement in iron metabolism, transport, storage, or regulation
(e.g., the hepcidin pathway). SNPs mapping to the following iron-
regulatory and transport genes were selected for this exploratory
analysis based on their inclusion in the Affymetrix Genome-Wide
Human SNP Array 6.0: HFE, HFE2, SLC40A1, SLC11A1,
HAMP, TF, TFRC, TFR2, BMP2, BMP6, CP, SLC11A2, FXN,
FTMT, FTH1, ACO1, ACO2, B2M and ATP13A2. Nineteen of
these genes were covered by the Affymetrix 6.0 chip, and the
platform provided evaluable genotypic information for 192
candidate SNPs (Table S1). Many of these iron-related genes/
SNPs have also been previously reported to play a role in iron
transport within the nervous system, and genes previously linked to
neurodegenerative diseases and neural differentiation were
included [35]. Based on the common disease-common variant
hypothesis, this list was further narrowed to those SNPs with
MAFs of at least 5% in one or both of the largest subsets of the
CHARTER study population (non-Hispanic blacks or non-
Hispanic whites, henceforth referred to as blacks or whites,
respectively) [36]. Using a typical analysis strategy that has been
applied in numerous previous studies, we used all available
genotyped SNPs in those genes, though some of them may be
correlated due to LD structure.
Statistical methods
General approach. The role of iron-related genes in
susceptibility to cART-associated HIV-SN and DNP was evalu-
ated by both multivariable logistic regression and permutation
analysis. Since the SNPs analyzed could not be assumed to be
independent, Bonferroni adjustment of statistical tests would
almost certainly overcorrect and result in unacceptable Type II
error; permutation-based analysis is a complementary statistical
method that accounts for multiple statistical tests, gene size, and
linkage disequilibrium [37,38]. Specifically, the observed p-value
from the real dataset is compared to the distribution of p-values
generated from 1000 permutated sample sets which randomly
switch case/control labels while maintaining the same case/
control ratio [37]. An empirical p-value is generated by the
number of permutation sets whose p-values are less than the
observed p-value divided by 1000.
Population stratification was also evaluated in our analyses by
adjustment for four principal components variables (PCs) repre-
senting ancestry-related genetic information, which were generat-
ed from genome-wide genotype data in CHARTER and used as
covariates in multivariate logistic regression models, in addition to
adjustment for self-reported race/ethnicity. Logistic regression
models stratified by self-reported race/ethnicity were also explored
(black or white; other categories were omitted due to insufficient
numbers). The degree of potential overlap between individual PCs
was also evaluated by plotting these variables against one another
(Figure S1).
The following neuropathy outcomes were analyzed: presence of
at least 1 sign of HIV-SN, at least 2 signs of HIV-SN, and DNP.
Each outcome was analyzed as a dichotomous variable. Potential
confounders were identified by univariable logistic regression to
calculate unadjusted odds ratios (ORs) and by prior published
associations of these variables with HIV-SN, neuropathy symp-
toms (loss of sensation, paresthesias, and/or dysesthesias/DNP), or
DNP alone in CHARTER.[1,9,33]. Significant variables were
then included in all multivariable logistic models with or without
race-stratification. These phenotype-specific covariates were as
follows: age (years), cumulative D-drug exposure (months), CD4+
T-cell nadir, log10[plasma HIV RNA], hepatitis C virus (HCV)
serologic status (positive/negative), protease inhibitor use (0 or $1
protease inhibitor), current or prior major depressive disorder
(yes/no), self-reported race (in non-stratified models), and the 4
genomic sequence-derived ancestry PC variables in HIV-SN
analyses; and age, cumulative D-drug exposure, CD4+ T-cell
nadir, log10[plasma HIV RNA], self-reported race (in non-
stratified analyses), and the 4 PC variables in analyses of
neuropathy symptoms and DNP. In order to account for the
effects of diabetes in some subjects who might also be on treatment
for this condition, we used a more stringent blood glucose criterion
for ascertaining diabetes than is normally used for non-fasting
blood glucose levels ($126 mg/dL, rather than $200 mg/dL). By
this criterion, 66 subjects (11.8%) were coded as diabetic. Since
additional adjustment for diabetes by this method did not alter p-
values appreciably for any of the studied SNPs, we did not include
this covariate in final regression models. (Hemoglobin A1c levels,
which would have allowed for more accurate diabetes diagnosis,
were available in ,10% subjects, and blood glucose values were
missing in 6 subjects.)
The reported associations of genetic variants with presence or
absence of HIV-SN or DNP made no genetic model assumptions
regarding dominant or recessive allelic effects (genotypes were
coded as 0, 1, or 2, based on the number of minor alleles present);
all SNPs in the genes studied were bi-allelic.
For analysis of DNP severity, genotypes were dichotomized
(variant alleles present or absent) to optimize power, and p-values
were obtained using Pearson’s chi-square test or, for those SNPs
with fewer than 5 observations per cell, Fisher’s exact test.
Multivariable single-SNP analyses. Statistical tests were
performed using publicly available R software (http://www.r-
project.org/). For each phenotype, logistic regression was used for
single-marker association tests, while adjusting for phenotype-
specific covariates in addition to race as a categorical covariate and
ancestry PCs, as discussed above [1,9]. Additional adjustment for
cART-naı¨ve status beyond inclusion of D-drug exposure and HIV
viral load did not significantly alter results; hence, this variable was
not included in multivariable models. PC variables were computed
in advance based on genome-wide genotype data available in all
560 CHARTER study participants. Permutation tests were
Iron-Regulatory Genes and HIV-Associated Neuropathic Pain
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conducted by randomizing case/control labels in multivariable
models while keeping the same numbers of cases and controls as in
the original dataset. We generated 1000 permutation datasets. An
empirical p-value was computed for each SNP in each phenotype,
according to pemp =#{P(p) ,P(real)/1000, where P(p) is the p-
value in the pth permutation [38,39].
Results of association tests for two key genes, CP and ACO1,
with neuropathic pain were depicted using the LocusZoom tool
(Figure 1, generated using HapMap Phase II CEU) [40].
The p-values for all statistical tests were two-tailed, and for this
exploratory analysis, the value of a (statistical significance) was set
at 0.05 to identify SNPs of potential interest in this exploratory
study. A Bonferroni correction for multiple statistical tests was also
applied by multiplying p-values obtained for each association test
by 192, the number of SNPs evaluated to identify more robust
associations.
Results
Genotypes from the CHARTER genome study were available
for 192 SNPs encompassing 19 iron-regulatory or iron-transport-
related (ferrome) genes queried (Table S1): HFE, HJV, FPN1,
SLC11A1, HAMP, TF, TFRC, TFR2, BMP2, BMP6, CP,
Figure 1. Representative Linkage Disequilibrium (LD) plot. The LD plot for two representative SNPs that were statistically significantly
associated with neuropathic pain in the CHARTER cohort is displayed: CP rs3816893 and ACO1 rs2026739. Each plot shows the degree of LD between
the SNP of interest (rs number) and all other SNPs analyzed in the same gene, color-coded according to the r2 value (correlation of frequencies in this
sample). The LD is based on HapMap Phase II CEU data. Association p-values are displayed on the y-axis and chromosomal distance (Mb) on the x-
axis.
doi:10.1371/journal.pone.0103123.g001
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SLC11A2, FXN, FTMT, FTH1, ACO1, ACO2, B2M, and
ATP13A2. Genotypes at the HEPH locus on the X chromosome,
which encodes a ceruloplasmin-like, membrane-bound ferroxidase
that is important in transmembrane iron transport, and genotypes
at the HFE C187G locus (previously studied by the authors in
HIV-infected subjects) were not covered by the Affymetrix Human
SNP Array 6.0 platform. The CHARTER genomic study
provided genotypes at all other loci of interest in .99% of
subjects; of 559 evaluable individuals, 21% were women, and the
mean age of the population was 44 years (range 21–68). Self-
reported race/ethnicity was 43% (n = 242) black, 44% (n = 247)
white, 11% (n = 58) Hispanic, and 2% Asian or ‘‘Other’’ (n = 11).
Due to insufficient power for analyses in subjects of Hispanic,
Asian or ‘‘Other’’ ancestry, only analyses performed in non-
Hispanic blacks, whites, or the entire CHARTER genetic study
population are reported. As shown in Figure S1, the 4 genome-
derived PC variables in multivariable models of neuropathic pain
accurately represented distinct ancestral strata in this study
sample.
Demographic and HIV disease characteristics of subjects with
and without HIV-SN are presented in Table 1. Among 559
evaluable subjects, 331 (59%) had at least one sign of HIV-SN,
and 160 (29%) exhibited more severe HIV-SN (at least two signs).
Fifty percent of the study population (281 subjects) reported at
least one neuropathic symptom, including paresthesias, loss of
sensation, dysesthesias, and/or DNP in both lower extremities.
Ascertainment of dysesthesias correlated so closely with DNP that
only results for DNP will be discussed henceforth. A total of 168
subjects (30% of this study sample) experienced DNP of some
degree of severity. CHARTER study subjects with HIV-SN (at
least one sign) and those who reported neuropathic symptoms
and/or DNP were older than subjects without these complications
(p,0.01). No significant differences were noted with regard to
educational level (data not shown), self-reported race/ethnicity, or
sex, but subjects reporting DNP tended to be female (26% vs.
19%, p= 0.06). Individuals with HIV-SN of any severity and those
who reported neuropathy symptoms other than DNP had a lower
CD4 nadir than corresponding controls [median (IQR) for cases
vs. controls, respectively, were 112 (31, 246) vs. 242 (125, 391)
cells/mL, p,0.01 for at least one HIV-SN sign; 107 (23, 214) vs.
200 (70, 350), p,0.01 for at least two signs; and 151 (37, 275) vs.
198 (60, 348), p,0.01 for neuropathy symptoms]. Median viral
load was lower among HIV-SN cases than controls [median (IQR)
1.7 (1.7, 3.3) vs. 2.6 (1.7, 4.2) log10 (HIV RNA copies/mL),
respectively, p,0.01] but not statistically different between
subjects with or without neuropathy symptoms and DNP.
Substantially fewer individuals with HIV-SN and DNP were
cART-naı¨ve as compared to controls (6% of cases with at least one
sign of HIV-SN vs. 29% of controls; 8% of DNP cases vs. 19% of
controls, p,0.01 for both). Cumulative D-drug exposure was also
higher among cases than controls in all outcome categories,
including DNP [e.g., median (IQR) 14 (0, 53) vs. 0 (0, 21) months
for DNP]; all p-values,0.01]. HIV-SN of any severity was
associated with the use of protease inhibitors (53% current use in
subjects with at least one sign vs. 31% of controls, p,0.01. Co-
infection with hepatitis C virus (HCV) was more common among
HIV-SN cases (28% of cases with at least one sign vs. 19% of
controls; 31% of cases with at least two signs vs. 22% of controls,
p,0.05 for both). History of a major depressive disorder was more
frequently reported by subjects without HIV-SN (46%) than
among HIV-SN cases (36%, p,0.05) and was slightly more
common among individuals with DNP.
Results of multivariable logistic regression and permutation
analyses evaluating associations of selected SNPs with HIV-SN
phenotypes, including DNP, are summarized in Table 2, adjusted
for potential confounders, including self-reported race and 4 PC
variables that captured racial admixture. Twelve SNPs in 8 iron-
related genes were associated with at least one sign of HIV-SN (p,
0.05) by permutation analyses, as compared with 13 SNPs in the
same 8 genes analyzed by logistic regression. One variant
(rs1049296 in the gene TF) was also associated with HIV-SN
with a p-value,0.01. One variant in the HFE gene was also
associated with reduced risk of HIV-SN in this population,
replicating a prior association of this gene with reduced risk of
HIV-SN [31]. More severe HIV-SN was associated with 10 SNPs
in 7 iron-related genes (p,0.05) and with 4 SNPs in 4 genes (p,
0.01) by permutation analysis. Fourteen SNPs in 8 iron-regulatory
genes were significantly associated with DNP (p,0.05) by logistic
regression and 15 SNPs by permutation analysis, including two
variants (rs3816893 in the gene CP and rs2026739 in the gene
ACO1). These SNPs were also associated with more severe HIV-
SN (at least two signs, data not shown). Eighteen SNPs in 6 genes
were associated in permutation analysis with the presence of one
or a combination of uncomfortable neuropathy symptoms
(paresthesias, loss of sensation, or dysesthesias/DNP, p,0.05).
Four variants in 2 of these genes, including CP rs3816893 and CP
rs13072552, were strongly associated with neuropathy symptoms
by logistic regression (all p-values,0.01) as well as by permutation
analysis (p,0.0001 for both SNPs mentioned), thereby also
meeting criteria for significance after correction for multiple
testing.
A summary of iron-regulatory gene variants significantly
associated in multivariable-adjusted analyses with DNP in
CHARTER subjects stratified by self-reported race, with estimat-
ed ORs and 95% confidence intervals (CIs), is presented in
Table 3. Eight iron-regulatory or iron-transport-related genes, TF,
CP, TFRC, BMP6, ACO1, FXN, SLC11A2, and B2M were
associated with DNP. Five SNPs in 4 iron regulatory genes, TF
rs2718796, CP rs13072552 and rs3816893, ACO1 rs2026739, and
B2M rs16966334, were associated with increased risk in the
combined CHARTER population by both logistic regression and
permutation analysis in the entire population, with ORs ranging
from 1.5 to 3.1 (all p,0.01). Race-stratified analyses revealed,
however, that statistically significant associations for some of these
SNPs occurred primarily within black or white subgroups. Point
estimates for the associations of CP rs3816893 and B2M
rs16966334 with DNP were greater in blacks than in whites and
statistically significant only in blacks [OR 2.6 (95% CI 1.3–5.0)
and 2.8 (95% CI 1.3–6.0), respectively, both p,0.01], while those
for ACO1 rs2026739 and B2M rs1901531 were statistically
significant among whites only [OR 2.3 (95% CI 1.4–3.7, p,
0.0001) and OR 2.2 (95% CI 1.3–3.8, p,0.01), respectively].
With the exception of B2M rs1901531, point estimates for ORs
associating SNPs with DNP in this population were consistent in
direction and very similar in magnitude across race-stratified
analyses (black and white subgroups). Several additional SNPs
were nominally associated with DNP by logistic regression as well
as permutation-based methods of analysis, including FXN
rs3793451 (all p,0.05). Two variants, TF rs8177306 and ACO1
rs4495514, could not be analyzed in whites due to insufficient
numbers of variant alleles.
The strong association of SNP rs2026739 in ACO1 with DNP in
whites by both logistic regression and permutation analysis
remained statistically significant after adjustment for multiple
testing (pemp,0.0001). Notably, no linkage disequilibrium was
observed between statistically significant SNPs and other SNPs
within the same genes, as exemplified in the LD maps for CP and
ACO1 (SNPs rs3816893 and rs2026739), shown in Figure 1.
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The prevalence of ferromic variants was compared across three
categories of severity of DNP, which was graded as none (0); slight
or mild (1–2); and moderate to severe (3–4) in race-stratified
analyses (Table 4). Only associations with p-values#0.05 are
presented. Polymorphisms in ACO1 (rs2026739), B2M
(rs16966334 and rs1901531), CP (rs3816893), TF (rs2718796
and rs8177306), and TFRC rs480760, most of which are very
common among both blacks and whites, showed statistically
significant associations with DNP severity in one or both
subgroups as well as in the entire study population.
Discussion
This represents the first study to associate key iron-regulatory
and iron-transport-pathway genes, which make up the human
ferrome and are critical for maintenance of neuronal metabolism
and mitochondrial function, with painful neuropathy in HIV-
infected subjects. Our results particularly support the concept that
iron metabolism plays a role in the pathophysiology of DNP for
the following reasons: 1) the same genomic variants showed
associations with DNP by conventional regression and by
permutation-based analytical methods, which account for the
effects of multiple statistical tests, gene size, and linkage
disequilibrium; 2) thirteen of the same SNPs (in 7 genes) were
also associated with the severity of DNP in this population; and 3)
point estimates for ORs were consistent in direction and very
similar in magnitude in both blacks and whites, as might be
anticipated for valid, fundamental biological associations. Fur-
thermore, ACO1 SNP rs2026739 retained its statistically signif-
icant association with DNP after adjustment for multiple testing.
Our observation that associations of certain SNPs (e.g., in CP,
ACO1, TF, and B2M genes) with DNP and with DNP severity
predominate in either blacks or whites may in part explain
reported population differences with regard to pain threshold and
pain-related disability, albeit in non-HIV-infected populations
[41,42]. Interaction with race-specific genomic and lifestyle factors
within these population subgroups is also possible. With the
exception of BMP6, none of the genes we associated with DNP
occurs on chromosome 6p, indicating that genomic variation in
iron metabolism and transport per se, not linkage disequilibrium
with HLA Class I-linked haplotypes that modulate inflammation,
is likely to be responsible for the observed associations.
Several lines of evidence support a role for iron metabolism in
the development of HIV-SN and/or DNP, which remain
significant problems even in the era of newer-generation cART
[43,44]. Common variants in the iron-loading HFE gene were
associated with reduced risk of HIV-SN during mitochondrial-
toxic cART regimens in AIDS Clinical Trial Group Study 384,
and the protective association with HFE was replicated in this
study [31]. HIV infection itself induces cellular iron dysregulation,
possibly via downregulation of macrophage Hfe expression by the
viral Nef protein and induction of the pro-inflammatory, iron-
regulatory hormone hepcidin [45–47]. Restless legs syndrome
(RLS), a disorder characterized by unpleasant sensations in the
lower extremities that are relieved by movement, has been
reported in some studies to be more prevalent in HIV-infected
individuals with painful neuropathy and has been likened to a
unique form of neuropathic pain [48,49]. Systemic iron deficiency,
brain iron deficiency, and activation of the hypoxia-inducible
factor pathway have been linked to the development of RLS, and
in a significant subset of patients, iron supplementation alleviates
symptoms [50–52]. The biological plausibility of a role for iron
metabolism in the pathophysiology of inflammatory peripheral
neuropathy and DNP is also suggested by prior experimental
studies and growing appreciation within the field of iron
metabolism of the importance of iron transport and its tight
regulation to maintenance of energy metabolism in highly
metabolically active cells such as neurons, and to immune
regulation [27,47,53–57]. Iron transport is critical to neuronal
energy metabolism and axoplasmic transport [58–60]. Inhibitors
of heme oxygenase, which catalyzes the breakdown of heme to
iron, biliverdin and carbon monoxide, have been shown to have
analgesic effects in some models of inflammatory or neuropathic
pain [61]. Genetic variation in iron transport has also been
associated with altered inflammatory cytokine levels, which at least
in part mediate neuropathic pain [62–66]. Involvement of bone
morphogenetic proteins in pain perception and sensitivity has also
been reported in rodent models [67].
The ACO1 and FXN genes are important for cellular energy
metabolism and mitochondrial iron transport: ACO1 encodes a
bifunctional protein containing an iron-sulfur cluster that revers-
ibly binds to regulatory elements in transferrin receptor (Tfr) and
ferritin mRNAs depending on ambient cellular iron levels [55].
This protein functions as a cytoplasmic aconitase under low-iron
conditions, upregulating synthesis of Tfr (the major cellular iron
importer) by stabilizing Tfr mRNA, while preventing translation of
ferritin (the principal iron storage protein in the cell); the reverse
occurs when ambient iron levels are high [68]. The FXN gene,
Table 2. Summary of significant results from multivariable analyses of peripheral neuropathy in CHARTER subjects.
Neuropathy Phenotype p-values from Logistic regression* Empirical p-values from Permutation*
No. of Significant genes (SNPs)
p,0.05 p,0.01 pemp,0.05 pemp,0.01
HIV-SN, $1 sign 8 (13) 1 (1) 8 (12) (0)
HIV-SN, $2 signs 7 (12) 4 (4) 7 (10) 4 (4)
Neuropathic pain 8 (14) 4 (5) 8 (15) 4 (5)
$1 Neuropathy symptom(s)¥ 7 (18) 2 (4) 6 (18) 2 (4)
*Models shown were adjusted for the following covariates: age, cumulative D-drug exposure, CD4+ T-cell nadir, plasma HIV RNA concentration, self-reported race,
protease inhibitor use, HCV status, history of major depression, and 4 ancestry by principal components (for HIV-SN); first five of the same factors plus principal
components (for neuropathic pain or neuropathy symptoms).
¥Includes presence of paresthesias, loss of sensation, and/or dysesthesias/neuropathic pain.
Analyses were performed with no genetic model assumptions (genotypes at each locus were coded as 0, 1, or 2 minor alleles).
Abbreviations: HIV-SN, HIV-sensory neuropathy.
doi:10.1371/journal.pone.0103123.t002
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which is mutated in Friedreich’s ataxia, regulates mitochondrial
iron utilization and export; a defect in the encoded frataxin
molecule in this disease results in progressive mitochondrial iron
accumulation and oxidative injury in a variety of tissues with high
metabolic demand, including the heart and central nervous system
[69–71]. Beta-2 microglobulin is a ubiquitous iron- and Hfe-
stabilizing protein which also promotes nerve repair following
injury, and it is a marker of disease progression in a variety of
diseases, but it has not previously been associated with DNP [72].
The CP rs3816893 and rs1302552 SNPs, which were associated
with DNP alone in this population, also showed strong associations
with the presence of neuropathy symptoms in general, which
included paresthesias and loss of sensation. These SNP associa-
tions also met multiple-testing criteria for significance after
permutation analysis, lending support to a role for CP in DNP.
Ceruloplasmin is a ferroxidase of critical importance to neuronal
copper and iron regulation and in neuronal protection against
iron-mediated oxidative injury in the central and peripheral
nervous systems [73]. The non-synonymous CP SNP rs13072552
has been associated in genome-wide association studies with
higher serum ceruloplasmin levels [74]. While serum ceruloplas-
min is an acute-phase reactant (levels rise during acute inflamma-
tion), serum ceruloplasmin levels may also be a marker of oxidative
neuronal injury, as in diabetic neuropathy.[75]. Disturbances in
ceruloplasmin homeostasis have been linked to other neurode-
generative diseases, and to neuropathic pain in the constriction
injury rat model of neuropathic pain.[76]. Similarly, transferrin
levels have been associated with peripheral neuropathy after
bariatric surgery, which has been shown to disrupt iron
homeostasis [77].
Iron transport in all tissues is intricately balanced with cellular
and mitochondrial iron demand; indeed, recent studies including
our own suggest that iron levels regulate mitochondrial biogenesis,
a determinant of mitochondrial function [78]. (Kallianpur et al,
unpublished data) Therefore, it should not be surprising if altered
iron transport increases susceptibility to HIV-SN and DNP,
especially in individuals exposed to mitochondria-toxic forms of
cART. Mitochondrial injury, as well as activation of glia in the
spinal cord and dorsal root ganglia due to HIV envelope
glycoprotein gp120, with consequent release of inflammatory
cytokines, may be involved in the pathogenesis of DNP [79].
Finally, others have reported that dysregulated iron transport also
alters glutamate metabolism, which is implicated in both drug-
induced and non-toxic peripheral neuropathies [80–82].
This study has some acknowledged limitations. The functional
effects of these SNPs in iron-related genes are currently unknown.
Since regulation of iron metabolism occurs largely at the post-
transcriptional level, we speculate that many of these variants alter
gene regulation and protein levels rather than protein structure or
function. Assay of serum protein levels was not possible as part of
this study, but CP rs13072552 has been linked to increased
ceruloplasmin levels [74], and several of the genes identified here
encode measurable serum proteins that may be investigated in
future studies. The functional relatedness of the genes we selected
in iron metabolism, in addition to tightly coordinated regulation of
some of these genes (e.g., ACO1 and TFRC) in order to fine tune
cellular iron access, storage, and utilization, argue against reliance
on genome-wide levels of significance or stringent multiple-testing
corrections in an exploratory study of this type; individual iron-
regulatory SNP genotypes are highly unlikely to be independent,
as represented in Figure 1. In this situation, correction for the
number of genes analyzed may be a more logical approach: with
this type of correction, TF rs2718796, CP rs3816893, and B2M
rs16966334, as well as ACO1 rs2026739 in whites, remain
statistically significant or nominally significant. (As noted, the
ACO1 SNP also remained significant after Bonferroni correction
for multiple tests.) We did not adjust in our analyses for height or
alcohol consumption, factors which can influence susceptibility to
neuropathy, but not necessarily DNP. However, alcohol con-
sumption was not associated with DNP on univariable analysis.
Information about hair color, which has been correlated with
neuropathic pain sensitivity, was not available [83]. We also
attempted to address the potential effect of diabetes on genetic
associations with peripheral neuropathy and DNP in this
population. Glycosylated hemoglobin values were not available
for analysis on most subjects, but additional adjustment for the
possible presence of treated or untreated diabetes, ascertained
using a more stringent-than-normal cut-off for non-fasting blood
glucose values, did not significantly impact our results. Finally, the
purpose of this study was to build on our prior findings of iron-
related genetic associations with HIV-SN and to test the
hypothesis that iron metabolism, rather than inflammation alone,
plays a role in HIV-associated DNP; we intentionally did not study
an exhaustive list of iron-regulatory genes. Much of the ferrome
therefore remains to be studied. Keltner et al recently reported
that HIV-associated DNP is associated in CHARTER subjects
with reduced total cortical gray matter volumes on neuroimaging;
cortical gray matter volumes have also been linked to R2*
relaxation times, a sensitive measure of brain iron content [84,85].
In summary, SNPs in eight iron-related genes selected for
analysis showed significant and biologically plausible associations
with DNP, independent of known potential confounders; SNPs in
7 of these genes also predicted DNP severity, adding to the
biological plausibility argument. Most importantly, the common
ACO1 rs2026739 variant remained significantly associated with
DNP and DNP severity after stringent correction for multiple tests.
Furthermore, associations with DNP were relatively robust, and
point estimates for SNP associations were similar in direction and
magnitude in blacks and whites, if not statistically significant in
both groups. These results support the concept that the ferrome
may be involved in the pathogenesis of HIV-SN and DNP in HIV-
infected individuals on cART. These new genetic associations will
require replication in other population samples as well as further
functional characterization to determine underlying biological
mechanisms that may be therapeutically targeted.
Supporting Information
Figure S1 Minimal overlap between ancestry principal
components (PCs). PCs plotted against one another demon-
strate appropriate clustering, with few outliers. Black dots: black;
blue dots: Hispanic; red dots: white; cyan dots: other.
(TIF)
Table S1 Iron-related genes and variants evaluated in
relation to neuropathy in CHARTER.
(PDF)
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